Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 14/20 | 0.64 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.56 |
| ▸ | AURKA | O14965 | 2/20 | 0.56 |
| ▸ | PTK6 | Q13882 | 3/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | TTK | P33981 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1674403 | 0.91 | MAPKAPK5 (0.63) | MAPKAPK5AURKBAURKAPTK6LCK | |
| SCHEMBL4399765 | 0.88 | MAPKAPK5 (0.58) | MAPKAPK5AURKBAURKAPTK6LCK | |
| SCHEMBL5574882 | 0.88 | MAPKAPK5 (0.55) | MAPKAPK5AURKBAURKAPTK6LCK | |
| SCHEMBL2678104 | 0.88 | MAPKAPK5 (0.60) | MAPKAPK5AURKBAURKAPTK6LCK | |
| SCHEMBL1674322 | 0.86 | MAPKAPK5 (0.63) | MAPKAPK5AURKBAURKAPTK6LCK | |
| SCHEMBL5575570 | 0.86 | MAPKAPK5 (0.58) | MAPKAPK5AURKBAURKAPTK6LCK | |
| SCHEMBL1674071 | 0.85 | MAPKAPK5 (0.70) | MAPKAPK5AURKBAURKAPTK6LCK | |
| SCHEMBL1674085 | 0.85 | MAPKAPK5 (0.58) | MAPKAPK5AURKBAURKAPTK6LCK | |
| SCHEMBL15063040 | 0.84 | MAPKAPK5 (0.69) | MAPKAPK5AURKBAURKAPTK6LCK | |
| SCHEMBL1674386 | 0.84 | MAPKAPK5 (0.74) | MAPKAPK5AURKBAURKAPTK6LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070281943-A1 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-06 | — | — | US | claimed |
| US-8178530-B2 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-15 | — | — | US | disclosed |
| US-8178530-B2 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-15 | — | — | US | disclosed |
| US-8173656-B2 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-08 | — | — | US | disclosed |
| US-8173656-B2 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-08 | — | — | US | disclosed |
| US-20110218178-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA NV | 2011-09-08 | — | — | US | disclosed |
| US-20110218178-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA NV | 2011-09-08 | — | — | US | disclosed |
| US-20110092497-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA NV | 2011-04-21 | — | — | US | disclosed |
| US-20110092497-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA NV | 2011-04-21 | — | — | US | disclosed |
| US-7893058-B2 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-22 | — | — | US | disclosed |
| US-20070281943-A1 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218178-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IKZF3, IRAK2, IRAK1 | MAPKAPK5 13/4885AURKB 3575/4885AURKA 3073/4885 |
| US-20110092497-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IKZF3, IRAK2, IRAK1 | MAPKAPK5 13/4885AURKB 3575/4885AURKA 3073/4885 |
| US-20070281943-A1 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | IKZF3, IRAK2, IRAK1 | MAPKAPK5 13/4885AURKB 3575/4885AURKA 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.